熱門資訊> 正文

在Roth购买了Brinsuri和Arikayce销售的新产品

2026-01-23 23:29

Insmed Incorporated(INSM) 0

Roth has initiated Insmed (INSM) at buy saying it sees above consensus sales of Brinsupri (brensocatib) and Arikayce (amikacin liposome inhalation suspension).
The firm set a $212 price target (~32% upside based on Jan. 22 close).
Analyst Adam Walsh sees Brinsupri peak sales of $8.1B and for Arikayce, $1.3B.
Walsh also highlighted the potential of treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension given positive mid-stage trial results released in June 2025. He sees $5B probability of success-adjusted peak sales.

More on Insmed

Insmed Incorporated (INSM) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
Insmed Incorporated (INSM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Insmed Impresses With Pulmonary Portfolio, But Still Lacks Remedy To Turn A Profit
Insmed gains as preliminary 2025 revenue beats consensus
Insmed drops as it abandons brensocatib in rhinosinusitis

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。